Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A

Published:2015-01-13 Issue:3 Volume:21 Page:343-350
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Kepa S.¹,Horvath B.²,Reitter-Pfoertner S.¹,Schemper M.³,Quehenberger P.²,Grundbichler M.⁴,Heistinger M.⁵,Neumeister P.⁶,Mannhalter C.²,Pabinger I.¹

Affiliation:

1. Clinical Division of Haematology and Haemostaseology; Department of Medicine I; Medical University of Vienna; Vienna Austria

2. Department of Laboratory Medicine; Medical University of Vienna; Vienna Austria

3. Center for Medical Statistics, Informatics and Intelligent Systems; Medical University of Vienna; Vienna Austria

4. Division of Haematology and Oncology; Department of Internal Medicine III; Medical University of Salzburg; Salzburg Austria

5. Department of Internal Medicine I; Clinical Centre of Klagenfurt am Woerthersee; Klagenfurt am Woerthersee Austria

6. Division of Haematology; Department of Internal Medicine; Medical University of Graz; Graz Austria

Funder

Austrian Haemophilia Society

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12592/fullpdf

Reference36 articles.

1. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens;Collins;J Thromb Haemost,2010

2. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia;Ahnström;Haemophilia,2004

3. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

4. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen;Fischer;Haemophilia,2002

5. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring;Björkman;J Thromb Haemost,2010

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A;Journal of Thrombosis and Haemostasis;2024-07

2. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A;Blood Advances;2024-05-30

3. Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis;Journal of Thrombosis and Haemostasis;2023-12

4. Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers;BLOOD TRANSFUS-ITALY;2023

5. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF–FVIII clearance in thrombosis and hemostasis;Journal of Thrombosis and Haemostasis;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3